Objective: Our purpose was to measure the transfer of lamivudine ([-]-2'-deoxy-3'-thiacytidine) across the human placenta both alone and in the presence of zidovudine.
Study Design: Nine placentas from term, elective cesarean deliveries were analyzed with use of the ex vivo single cotyledon perfusion system. Antipyrine was used as the reference compound to measure the clearance index values of lamivudine alone and in combination with zidovudine. Lamivudine concentrations in the perfusates and tissues were quantified by high-pressure liquid chromatography.
Results: The clearance index of lamivudine at a maternal concentration of 1.39 micrograms/ml was 0.23 +/- 0.14. At a peak concentration of 14.68 micrograms/ml the clearance index was 0.14 +/- 0.06. These index values did not significantly change in the presence of 1 or 10 micrograms/ml of zidovudine. In a closed recirculating system the fetal lamivudine concentration increased as more lamivudine was added to the maternal perfusate. The addition of zidovudine did not influence this transfer.
Conclusion: Lamivudine appears to cross the placenta by simple diffusion and its transfer does not appear to be altered by zidovudine.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0002-9378(97)70487-3 | DOI Listing |
J Med Microbiol
January 2025
Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, PR China.
Lamivudine plus dolutegravir (3TC/DTG) and bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) regimens are commonly used as first-line treatments for people living with human immunodeficiency virus (HIV) (PLWH) worldwide. There are limited comparative data on the antiviral activity and safety between these regimens in ART-naive PLWH, particularly in China, where the 3TC/DTG regimen was integrated into first-line therapy in 2021 and gained broader adoption after its inclusion in the National Health Insurance in 2022. This study aims to provide real-world evidence comparing the 3TC/DTG regimen to the B/F/TAF regimen in ART-naive PLWH in China.
View Article and Find Full Text PDFViruses
December 2024
HIV Pathogenesis Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.
Islatravir (ISL) is the first-in-class nucleoside reverse transcriptase translocation inhibitor (NRTtI) with novel modes of action. Data on ISL resistance are currently limited, particularly to HIV-1 non-B subtypes. This study aimed to assess prevalent nucleos(t)ide reverse transcriptase inhibitor (NRTI)-resistant mutations in HIV-1 subtype C for their phenotypic resistance to ISL.
View Article and Find Full Text PDFPharmaceuticals (Basel)
December 2024
Viral Immunodeficiencies Unit, Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Via Portuense 292, 00149 Roma, Italy.
With advances in antiretroviral therapy for HIV treatment, newer drug combinations provide improved efficacy, safety, and compliance. This study evaluates switching to a regimen of doravirine (DOR), tenofovir disoproxil fumarate (TDF), and lamivudine (3TC) in a cohort of people living with HIV (PLWH). this Italian retrospective study included 426 PLWH who switched from rilpivirine (RPV)/TDF/emtricitabine (FTC) to DOR/3TC/TDF.
View Article and Find Full Text PDFBMC Infect Dis
January 2025
Department of Infectious Diseases, Hospital Universitario de Caracas, Caracas, Venezuela.
Background: Disseminated nocardiosis is a rare and potentially fatal disease, with a higher incidence in immunocompromised patients, such as those living with human immunodeficiency virus (HIV) or hematological malignancies, including lymphoma. Information on Nocardia spp. infection in Venezuela is limited.
View Article and Find Full Text PDFJ Chromatogr B Analyt Technol Biomed Life Sci
December 2024
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!